MOTION PROCESSING IN SCHIZOPHRENIA

精神分裂症的运动处理

• 批准号: 7608138
• 负责人: GUNVANT K THAKER
• 金额: $ 8.14万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608138
• 关键词: Biological; Categories; Cognitive; Communities; Computer Retrieval of Information on Scientific Projects Database; Diagnostic; Equipment; Exhibits; Eye Movements; Family history of; Funding; Genes; Goals; Grant; Individual; Institution; Invasive; Laboratories; Methods; Molecular Genetics; Motion; Motion Perception; Neurocognitive; Patients; Personality; Phase; Phenotype; Physiological; Process; Recruitment Activity; Relative (related person); Research; Research Personnel; Resources; Schizophrenia; Smooth Pursuit; Source; Standards of Weights and Measures; Subgroup; Symptoms; Testing; United States National Institutes of Health; Work; design

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Smooth pursuit eye movement abnormality (SPEM) is observed in about 40% of schizophrenic patients and a proportion of their non-ill, first-degree biological relatives. The latter suggests that the SPEM deficit marks schizophrenia liability. The goal of the current application is to identify the specific neurocognitive mechanisms underlying the SPEM phenotype in schizophrenia. A specific physiological deficit is likely to be more proximal to the effects of genes, and therefore more accurate in identifying a homogenous subgroup of individuals with schizophrenia liability. This work has significance for use of the refined phenotype in molecular genetic and pathophysiologic studies of schizophrenia. We will test patients with schizophrenia, their 1st degree relatives who show other evidence of schizophrenia liability (i.e., schizophrenia spectrum personality (SSP) symptoms, SSP), and community subjects with no family history of psychotic illness. The study will be carried in out in two phases. In the initial phase we will test groups of 5-10 subjects from each diagnostic category in order to insure that newly designed tasks and equipment are working properly. Once the pilot testing is completed, we will recruit 30 subjects with schizophrenia, 30 1st degree relatives with SSP, 60 healthy, community subjects with no family history of schizophrenia (30 of whom exhibit SSP symptoms in the absence of a family history of psychotic illness). A battery of cognitive, motion perception and eye movement tasks will be administered in these subjects. Some of the testing will be carried out in Dr. Turano's laboratory at Johns Hopkins. Standard non-invasive methods are used for all testing.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 大约 40% 的精神分裂症患者及其一部分未患病的一级生物学亲属存在平滑追踪眼动异常 (SPEM)。后者表明 SPEM 缺陷标志着精神分裂症的责任。当前应用的目标是确定精神分裂症 SPEM 表型背后的特定神经认知机制。特定的生理缺陷可能更接近基因的影响，因此可以更准确地识别患有精神分裂症的个体的同质亚组。这项工作对于在精神分裂症的分子遗传学和病理生理学研究中使用精细表型具有重要意义。我们将测试精神分裂症患者、其具有其他精神分裂症倾向证据（即精神分裂症谱系人格（SSP）症状，SSP）的一级亲属，以及没有精神病家族史的社区受试者。该研究将分两个阶段进行。在初始阶段，我们将对每个诊断类别的 5-10 名受试者进行分组测试，以确保新设计的任务和设备正常工作。试点测试完成后，我们将招募 30 名精神分裂症受试者、30 名患有 SSP 的一级亲属、60 名没有精神分裂症家族史的健康社区受试者（其中 30 名在没有精神病家族史的情况下表现出 SSP 症状）。这些受试者将接受一系列认知、运动感知和眼动任务。部分测试将在图拉诺博士位于约翰·霍普金斯大学的实验室进行。所有测试均使用标准非侵入性方法。